Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PRT062607

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis
Liver fibrosis and fibrosis-associated hepatocarcinogenesis are driven by chronic inflammation and are leading causes of… Expand
  • figure 1
  • figure 4
  • figure 5
  • figure 7
  • figure 8
Is this relevant?
2017
2017
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
B-cell receptor (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell… Expand
  • table 1
Is this relevant?
2013
2013
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis
BACKGROUND Selective disruption of the spleen tyrosine kinase (Syk) represents a novel strategy to control B-cell functional… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE